physalin B: has immunosuppressive activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
physalin B : A physalin with antimalarial, antitumour and antimicrobial activities isolated from Physalis angulata. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Physalis | genus | A plant genus of the family SOLANACEAE. Members contain physalin and withangulatin.[MeSH] | Solanaceae | A plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 11730919 |
| CHEBI ID | 69017 |
| SCHEMBL ID | 504410 |
| MeSH ID | M0103304 |
| Synonym |
|---|
| 23133-56-4 |
| physalin b |
| CHEBI:69017 |
| SCHEMBL504410 |
| Q27137361 |
Physalin B is a natural secosteroidal, extracted from the Solanaceae plant, Physalis angulata. It presents immune-modulator effects on the bloodsucking bug, Rhodnius prolixus.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Physalin B has shown efficacy as an anti-acute lung injury (ALI) agent previously; however, its mechanisms of action remain unclear. " | ( Physalin B ameliorates inflammatory responses in lipopolysaccharide-induced acute lung injury mice by inhibiting NF-κB and NLRP3 via the activation of the PI3K/Akt pathway. Chen, Y; Ding, Z; Li, C; Li, W; Peng, M; Shu, Z; Wang, Y; Xia, T; Zhang, H; Zhong, R, 2022) | 3.61 |
Physalin B could suppress DSS-induced activation of NF-κB. Physalin B did not inhibit catalytic activities of purified proteasome.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Physalin B could suppress DSS-induced activation of NF-κB." | ( Anti-colitic effects of Physalin B on dextran sodium sulfate-induced BALB/c mice by suppressing multiple inflammatory signaling pathways. Hu, X; Xu, N; Zhang, Q; Zheng, Y, 2020) | 1.59 |
| "Physalin B did not inhibit catalytic activities of purified proteasome and interfered with cellular proteasomal catalytic activities at 4- to 8-fold higher concentrations than that required to induce significant increase in bioluminescence and accumulation of ubiquitinated proteins in DLD-1 4Ub-Luc cells." | ( Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis. Annereau, JP; Aussagues, Y; Ausseil, F; Bailly, C; Barret, JM; Créancier, L; Kruczynski, A; Massiot, G; Pouny, I; Samson, A; Vandenberghe, I; Vispé, S, 2008) | 2.51 |
Physalin B-treated mice had lower levels of serum TNF-alpha than control mice after lipopolysaccaride challenge. Physalin B treatment dose-dependently increased the phosphorylation of p38, ERK and JNK in the cells.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Physalin B treatment dose-dependently increased the phosphorylation of p38, ERK and JNK in the cells, whereas the p38 inhibitor SB202190, ERK inhibitor U0126 or JNK inhibitor SP600125 could partially reduce physalin B-induced PARP cleavage and p62 accumulation." | ( Physalin B not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in human colon cancer cells in vitro. Han, W; Hu, LH; Li, J; Ma, YM; Zhou, YB, 2015) | 2.58 |
| "Physalin B-treated mice had lower levels of serum TNF-alpha than control mice after lipopolysaccaride challenge." | ( Inhibition of macrophage activation and lipopolysaccaride-induced death by seco-steroids purified from Physalis angulata L. Bellintani, MC; Ribeiro dos Santos, R; Ribeiro, IM; Soares, MB; Tomassini, TC, 2003) | 1.04 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " A pharmacokinetic study showed that physalin B has a long dwell time with a half-life of 321." | ( In vivo pharmacokinetics of and tissue distribution study of physalin B after intravenous administration in rats by liquid chromatography with tandem mass spectrometry. Chen, J; Hong, D; Liang, X; Liu, L; Zheng, Y, 2016) | 0.95 |
| Role | Description |
|---|---|
| antimalarial | A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| lactone | Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. |
| organic heteroheptacyclic compound | |
| physalin | Any seco-steroid based on a 13,14-seco-16,24-cycloergostane skeleton and its substituted derivatives thereof. These phytochemicals form the major steroidal constituents of Physalis plants and exhibit antimicrobial and antiparasitic activity. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 11 (28.21) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 42 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||